61 related articles for article (PubMed ID: 33762119)
1. PIM Kinase Inhibition Attenuates the Malignant Progression of Metastatic Hepatoblastoma.
Julson JR; Quinn CH; Butey S; Erwin MH; Marayati R; Nazam N; Stewart JE; Beierle EA
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203596
[TBL] [Abstract][Full Text] [Related]
2. Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma.
Stafman LL; Williams AP; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Beierle EA
Transl Oncol; 2019 Feb; 12(2):200-208. PubMed ID: 30412911
[TBL] [Abstract][Full Text] [Related]
3. Nur77 inhibition of β-catenin expression mediates Hepatoblastoma progression and enhances cisplatin's therapeutic effect.
Zhou J; Liu X; Yin H; Zhou Y; Xu Z; Zhou K; Li T; Fang Y; Shen Q
Gene; 2024 May; 908():148292. PubMed ID: 38369247
[TBL] [Abstract][Full Text] [Related]
4. Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma.
Abril-Fornaguera J; Torrens L; Andreu-Oller C; Carrillo-Reixach J; Rialdi A; Balaseviciute U; Pinyol R; Montironi C; Haber PK; Del Río-Álvarez Á; Domingo-Sàbat M; Royo L; Akers NK; Willoughby CE; Peix J; Torres-Martin M; Puigvehi M; Cairo S; Childs M; Maibach R; Alaggio R; Czauderna P; Morland B; Losic B; Mazzaferro V; Guccione E; Sia D; Armengol C; Llovet JM
Mol Cancer Ther; 2023 Apr; 22(4):485-498. PubMed ID: 36780225
[TBL] [Abstract][Full Text] [Related]
5. SGLT2 is upregulated to acquire cisplatin resistance and SGLT2 inhibition reduces cisplatin resistance in hepatoblastoma.
Fujiyoshi S; Honda S; Ara M; Kondo T; Kobayashi N; Taketomi A
J Hepatobiliary Pancreat Sci; 2024 Apr; 31(4):223-233. PubMed ID: 37927142
[TBL] [Abstract][Full Text] [Related]
6. Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids.
Song H; Bucher S; Rosenberg K; Tsui M; Burhan D; Hoffman D; Cho SJ; Rangaswami A; Breese M; Leung S; Ventura MVP; Sweet-Cordero EA; Huang FW; Nijagal A; Wang B
Nat Commun; 2022 Aug; 13(1):4878. PubMed ID: 36008377
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide mapping of cancer dependency genes and genetic modifiers of chemotherapy in high-risk hepatoblastoma.
Fang J; Singh S; Cheng C; Natarajan S; Sheppard H; Abu-Zaid A; Durbin AD; Lee HW; Wu Q; Steele J; Connelly JP; Jin H; Chen W; Fan Y; Pruett-Miller SM; Rehg JE; Koo SC; Santiago T; Emmons J; Cairo S; Wang R; Glazer ES; Murphy AJ; Chen T; Davidoff AM; Armengol C; Easton J; Chen X; Yang J
Nat Commun; 2023 Jul; 14(1):4003. PubMed ID: 37414763
[TBL] [Abstract][Full Text] [Related]
8. The Role of PIM Kinases in Pediatric Solid Tumors.
Julson JR; Marayati R; Beierle EA; Stafman LL
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892829
[TBL] [Abstract][Full Text] [Related]
9. Identification of Ten Core Hub Genes as Potential Biomarkers and Treatment Target for Hepatoblastoma.
Sun R; Li S; Zhao K; Diao M; Li L
Front Oncol; 2021; 11():591507. PubMed ID: 33868991
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells.
Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Markert HR; Easlick JL; Stewart JE; Crossman DK; Mroczek-Musulman E; Beierle EA
Cancer Gene Ther; 2022 May; 29(5):558-572. PubMed ID: 33864024
[TBL] [Abstract][Full Text] [Related]
11. Novel second-generation rexinoid induces growth arrest and reduces cancer cell stemness in human neuroblastoma patient-derived xenografts.
Marayati R; Bownes LV; Quinn CH; Wadhwani N; Williams AP; Markert HR; Atigadda V; Aye JM; Stewart JE; Yoon KJ; Beierle EA
J Pediatr Surg; 2021 Jun; 56(6):1165-1173. PubMed ID: 33762121
[TBL] [Abstract][Full Text] [Related]
12. Recent improvement in survival outcomes and reappraisal of prognostic factors in hepatoblastoma.
Koh KN; Namgoong JM; Yoon HM; Cho YA; Choi SH; Shin J; Kang SH; Suh JK; Kim H; Oh SH; Kim KM; Kim DY; Im HJ
Cancer Med; 2021 May; 10(10):3261-3273. PubMed ID: 33939313
[TBL] [Abstract][Full Text] [Related]
13. Reconciling the Biological and Transcriptional Variability of Hepatoblastoma with Its Mutational Uniformity.
Prochownik EV
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33919162
[TBL] [Abstract][Full Text] [Related]
14. Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer.
Hirsch TZ; Pilet J; Morcrette G; Roehrig A; Monteiro BJE; Molina L; Bayard Q; Trépo E; Meunier L; Caruso S; Renault V; Deleuze JF; Fresneau B; Chardot C; Gonzales E; Jacquemin E; Guerin F; Fabre M; Aerts I; Taque S; Laithier V; Branchereau S; Guettier C; Brugières L; Rebouissou S; Letouzé E; Zucman-Rossi J
Cancer Discov; 2021 Oct; 11(10):2524-2543. PubMed ID: 33893148
[TBL] [Abstract][Full Text] [Related]
15. A new risk-stratification system for hepatoblastoma in children under six years old and the significance for prognosis evaluation-a 14-year retrospective study from a single center.
Zhi T; Zhang WL; Zhang Y; Hu HM; Wang YZ; Huang DS
BMC Cancer; 2021 Apr; 21(1):397. PubMed ID: 33849485
[TBL] [Abstract][Full Text] [Related]
16. PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma.
Wadhwani N; Markert HR; Marayati R; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Beierle EA
J Pediatr Surg; 2021 Jun; 56(6):1157-1164. PubMed ID: 33762119
[TBL] [Abstract][Full Text] [Related]
17. PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.
Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Anderson JC; Willey CD; Beierle EA
Sci Rep; 2021 Mar; 11(1):5984. PubMed ID: 33727604
[TBL] [Abstract][Full Text] [Related]
18. Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.
Stafman LL; Mruthyunjayappa S; Waters AM; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Mroczek-Musulman E; Beierle EA
Oncotarget; 2018 Apr; 9(32):22665-22679. PubMed ID: 29854306
[TBL] [Abstract][Full Text] [Related]
19. The Effects of Protein Phosphatase 2A Activation with Novel Tricyclic Sulfonamides on Hepatoblastoma.
Bownes LV; Julson JR; Quinn CH; Hutchins SC; Erwin MH; Markert HR; Stewart JE; Mroczek-Musulman E; Aye J; Yoon KJ; Ohlmeyer M; Beierle EA
J Pediatr Surg; 2023 Jun; 58(6):1145-1154. PubMed ID: 36907775
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
